OMERS ADMINISTRATION Corp Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA

OMERS ADMINISTRATION Corp acquired a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 13,100 shares of the company’s stock, valued at approximately $631,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. KBC Group NV purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $34,000. Smartleaf Asset Management LLC purchased a new position in Kiniksa Pharmaceuticals International in the fourth quarter valued at $36,000. EverSource Wealth Advisors LLC raised its stake in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares in the last quarter. Nano Cap New Millennium Growth Fund L P acquired a new stake in Kiniksa Pharmaceuticals International in the fourth quarter valued at $41,000. Finally, CIBC Private Wealth Group LLC purchased a new stake in Kiniksa Pharmaceuticals International during the 4th quarter worth about $41,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently commented on KNSA shares. The Goldman Sachs Group increased their price objective on Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a report on Thursday. Wells Fargo & Company boosted their target price on Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Wedbush upped their price target on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a report on Wednesday. JPMorgan Chase & Co. increased their price target on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. One analyst has rated the stock with a Strong Buy rating and nine have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $87.38.

Key Headlines Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Multiple analysts raised price targets: Goldman Sachs increased its target to $90 and initiated a “buy” rating; JPMorgan raised its target to $107 with an “overweight” rating; Canaccord Genuity lifted its target to $98 and maintained a “buy” rating; Wedbush raised its target to $99 with an “outperform” rating; and Citi increased its target to $100 with a “buy” rating. The broad upward revisions signal growing confidence in KNSA’s commercial outlook and pipeline. Benzinga analyst price-target reports
• Positive Sentiment: Higher earnings estimates could support additional gains. Zacks reported that analysts are raising estimates for Kiniksa, a trend that often reflects improving expectations for future revenue and profitability. Zacks earnings estimates article
• Positive Sentiment: Raised 2026 guidance and pipeline progress drove the initial rally. Coverage highlighted Kiniksa’s stronger revenue outlook and advancement of its development pipeline, reinforcing expectations for continued growth. Yahoo Finance guidance and pipeline article
• Positive Sentiment: Quarterly results exceeded revenue expectations. Kiniksa reported $243.6 million in revenue versus the $226.5 million consensus estimate, while adjusted EPS of $0.30 matched expectations. Kalkine Media Kiniksa earnings announcement
• Negative Sentiment: Valuation is a risk after the sharp advance. One analysis suggested KNSA could be approximately 16% overvalued even after the guidance increase, potentially limiting upside or prompting profit-taking if growth expectations moderate. Yahoo Finance KNSA valuation article

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA stock opened at $78.20 on Friday. The stock’s 50-day moving average is $58.62 and its two-hundred day moving average is $50.96. The firm has a market cap of $6.02 billion, a price-to-earnings ratio of 80.62 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a 1 year low of $29.90 and a 1 year high of $82.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, meeting the consensus estimate of $0.30. The business had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. As a group, research analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.39 EPS for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.